Filing Analysis
💸 Securities Offering
Filed Dec 23, 2024
🟠 HIGH
Guided Therapeutics, Inc. entered into a Securities Purchase Agreement on December 18, 2024, to raise $535,000 in gross proceeds through the sale of common stock and warrants at a combined price of $0.13 per unit.
🚩 Red Flags
- Extremely low share/warrant price ($0.13) suggests a highly distressed valuation or potential risk of future reverse split to maintain exchange compliance.
- Related-party transaction: One of the institutional investors is John Imhoff, a member of the Company's Board of Directors.
- Small capital raise ($535k) relative to typical micro-cap operations suggests limited runway and high dependency on dilutive financing.
📋 Key Facts
- Gross proceeds: $535,000
- Total shares/warrants issued: 4,115,386 units
- Combined purchase price per Share and Warrant: $0.13
- Warrant exercise price: $0.18 per share
- Warrant expiration: Four years from issuance date
- Use of proceeds: General corporate purposes, working capital, and manufacturing expenses for international distribution orders.
💸 Securities Offering
Filed Sep 27, 2024
🟠 HIGH
Guided Therapeutics, Inc. entered into a Securities Purchase Agreement on September 23, 2024, to raise $300,000 in gross proceeds through a private placement of common stock and warrants.
🚩 Red Flags
- Extremely low share/warrant price ($0.09) suggests significant dilution and potential 'death spiral' financing characteristics
- Related-party transaction: An investor is a member of the Company’s Board of Directors (John Imhoff)
- Small capital raise ($300k) relative to typical micro-cap operations, indicating tight liquidity/cash runway concerns
📋 Key Facts
- Total gross proceeds: $300,000
- Securities issued: 3,333,335 shares of Common Stock and 3,333,335 Warrants
- Combined purchase price per Share and Warrant: $0.09
- Warrant terms: Immediately exercisable, expires in four years, exercise price of $0.12 per share
- Investors include John Imhoff, a member of the Company's Board of Directors
- Use of proceeds: General corporate purposes and working capital
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.